All In Biotech

Drug Trial Radar · NCT07807163

A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Bicara TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). The study aims to demonstrate that the antitumor activity of an alternative dosing regimen of ficerafusp alfa in combination with pembrolizumab is comparable to the weekly ficerafusp alfa regimen in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Conditions

  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

  • Ficerafusp alfaDrug

    investigational agent

  • Pembrolizumab (KEYTRUDA®)Drug

    immunotherapy agent used in combination with investigational agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.Time frame: Approximately 9 months.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site US077

    Fort Myers, Florida · Recruiting

  • Site US078

    Orlando, Florida · Recruiting

  • Site US075

    St. Petersburg, Florida · Recruiting

  • Site US076

    West Palm Beach, Florida · Recruiting

  • Site US069

    Baton Rouge, Louisiana · Recruiting

  • Site US074

    Tyler, Texas · Recruiting

  • Site US073

    Roanoke, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.